Bristol Myers Squibb Co. has prepared and tested proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to interleukin-1 receptor-associated kinase 4 (IRAK-4) targeting moiety through a linker reported to be useful for the treatment of autoimmune diseases and inflammatory disorders.
Biopharma dealmaking gained momentum in the second quarter (Q2) of 2025, surpassing the previous quarter and staying well above the 2024 quarterly average of $57.63 billion. Total deal value reached $71.45 billion across 278 transactions in Q2, rising from $66.86 billion and 333 deals in Q1. The quarter also marked a notable jump from Q2 of 2024, when $55.3 billion was raised through 360 agreements.
Philochem AG’s ligand-targeting approach drew to the table Bristol Myers Squibb Co. in a potential $1.35 billion agreement granting BMS subsidiary Rayzebio Inc. exclusive worldwide rights to OncoACP3, a diagnostic and therapeutic candidate targeting prostate cancer.
Biontech SE and Bristol Myers Squibb Co. are teaming up to develop Biontech’s BNT-327 in a deal possibly worth over $11 billion. BNT-327 is in the hot new class of bispecific antibodies targeting programmed death-1 (PD-1) or its ligand (PD-L1) and vascular endothelial growth factor (VEGF). The bispecifics take advantage of two well established mechanisms of action that help tumors grow; PD-1/PD-L1, which tells immunogenic T cells not to attack the tumor, and VEGF, which tumors excrete to produce new blood vessels to supply oxygen and other nutrients to the tumor.
Bristol Myers Squibb Co. has disclosed proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN) E3 ubiquitin ligase-binding moiety covalently bonded to a B-cell lymphoma 6 protein (BCL-6)-targeting moiety through a linker. They are reported to be useful for the treatment of cancer and autoimmune diseases.
Bristol Myers Squibb Co. has identified molecular glue degraders comprising cereblon ligands and a eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1)-targeting moiety acting as GSPT1 degradation inducers reported to be useful for the treatment of cancer.
Bristol Myers Squibb Co. has identified serum/glucocorticoid-regulated kinase 1 (SGK1) inhibitors reported to be useful for the treatment of fibrosis, cancer, cardiovascular, cerebrovascular, metabolic, inflammatory, neurological and immunological disorders, among others.
